Acuitas Therapeutics Inc. is a Canadian biotechnology company based in Vancouver, British Columbia. The company was established in February 2009 to specialize in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticle (LNP) technology, a key component of the mRNA vaccines deployed for COVID-19.[1][2]
History
Inex Pharmaceuticals
Pieter Cullis was among several scientists experimenting with liposomes in the early 1980s, fascinated by their properties in many aspects of human biology.[3] Cullis discovered he could load cancer drugs into liposomes, inspiring him and several colleagues at the University of British Columbia to form Inex Pharmaceuticals in 1992.[4]